1074-63-1

Basic information

• Product Name: 3-(CYCLOPENTYLAMINO)PROPIONITRILE
• Synonyms: 3-(CYCLOPENTYLAMINO)PROPIONITRILE
• CAS NO: 1074-63-1
• Molecular Formula: C₈H₁₄N₂
• Molecular Weight: 138.21
• Mol File: 1074-63-1.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 115-116°C 7mm
• Flash Point: 114.5 °C
• Appearance: /
• Density: 0,95 g/cm3
• Vapor Pressure: 0.00897mmHg at 25°C
• Refractive Index: 1.474
• Storage Temp.: 2-8°C
• PKA: 8?+-.0.20(Predicted)
• CAS DataBase Reference: 3-(CYCLOPENTYLAMINO)PROPIONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(CYCLOPENTYLAMINO)PROPIONITRILE(1074-63-1)
• EPA Substance Registry System: 3-(CYCLOPENTYLAMINO)PROPIONITRILE(1074-63-1)

Safety Data

• Statements: 20/21/22
• Safety Statements: 26-36/37/39
• RIDADR: 3276
• Hazardous Substances Data: 1074-63-1(Hazardous Substances Data)

Usage

General Description

3-(Cyclopentylamino)propionitrile is a chemical compound used in the pharmaceutical industry as an intermediate in the synthesis of various drugs. It is a nitrile compound with a cyclopentylamino group attached to a propionitrile moiety. 3-(CYCLOPENTYLAMINO)PROPIONITRILE has potential applications in the development of new drug molecules and pharmaceuticals due to its ability to modify biological activity. It is also used in the research and development of new therapeutic agents and drug formulations. Additionally, 3-(Cyclopentylamino)propionitrile is used as a building block in the synthesis of various organic and medicinal compounds, making it an important chemical in the pharmaceutical and chemical industries.

InChI:InChI=1/C8H14N2/c9-6-3-7-10-8-4-1-2-5-8/h8,10H,1-5,7H2

Upstream product

• 107-13-1 acrylonitrile 
• 1003-03-8 Cyclopentamine 

Relevant articles and documents

-

-

CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS

The subject matter herein is directed to carbazole-containing amide, carbamate, and urea derivatives and pharmaceutically acceptable salts or hydrates thereof of structural formula I wherein the variable R1, R2, R3, R4, R5, R6, R7, A, D, E, G, J, L, M, Q, a, and b are accordingly described. Also provided are pharmaceutical compositions containing the compounds of formula I to treat a Cry-mediated disease or disorder, such as diabetes, complications associated with diabetes, Cushing's syndrome, NASH, NAFLD, asthma, and COPD.

Synthesis and antiplatelet activity of new imidazole-4-carboxylic acid derivatives

1-Arylalkyl-5-phenylsulfonamino-imidazole-4-carboxylic acid esters and their carboxamides with an additional secondary amino group were synthesized and identified as antiplatelet agents in a low micromolar range (Born-test, inducer collagen). To describe the mechanism of action more precisely the Born-test was carried out as well with ADP, adrenaline or PAF, respectively. In addition, two compounds were investigated for their COX-1 inhibitory activities. Provided the essential structural criteria are met i.e. amide group or ester, sulfonylamino rest, hydrophobic moieties, and a secondary amino function, slight structural modifications are able to shift the pattern of activity among the above platelet receptors. So, the ester 5c exhibits PAF antagonistic activity at IC 50 = 1 μM and COX-1 inhibition (IC50 = 0.4 μM). The carboxamide 6c shows ADP antagonistic properties (IC50 = 2 μM). Compound 6g is as well PAF antagonistic (IC50 = 4 μM) and a COX-1 inhibitor (IC50 = 1 μM). The derivative 6i shows a strong antiadrenergic (IC50 = 0.15 μM) and PAF antagonistic (IC 50 = 0.66 μM) effect.